SecBot SecBot
PRESS-RELEASE ·Filed May 11, 2026

SCYX

Scynexis
BEARISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The significant EPS miss and widening operating losses are concerning, but the $72.4M cash runway to mid-2029 and upcoming SCY-770 Phase 2 catalyst in Q4 2026 provide a long development horizon. Monitor for topline Phase 1 IV data for SCY-247 in Q3 2026 and any GSK Brexafemme relaunch milestones that could trigger revenue.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.24
T+0 close · May 11, 2026 · via day close
Latest settled
−16.67%
T+60 · $5.20
Vs SPY
−21.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $6.24entry
  2. T+1 · 6mo ago −2.44%α −3.00% · $6.09
  3. T+5 · 6mo ago −15.77%α −15.17% · $5.26
  4. T+20 · 5mo ago −33.49%α −31.77% · $4.15
  5. T+60 · 3mo ago −16.67%α −21.05% · $5.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SCYNEXIS reported Q1 2026 results with a GAAP net loss of $0.42 per share, significantly wider than the consensus estimate of -$0.12, driven by a $8.0M IPR&D charge for the SCY-770 acquisition and a $5.2M warrant liability fair value adjustment. The company completed a $37.2M private placement and ended the quarter with $72.4M in cash, extending its runway to mid-2029, but the core operating loss more than doubled year-over-year with no revenue.

Key Financial Metrics

EPS
−$0.42
est −$0.12 · -250.0%
Revenue
$0.00
est $77.0K · -100.0% · -100.0% YoY
Rating
strong miss

Key Facts

  • GAAP net loss per share of -$0.42 vs consensus of -$0.12 (250% miss)
  • Net loss of $21.3M vs $5.4M in Q1 2025, driven by $8.0M IPR&D charge for SCY-770 acquisition and $5.2M warrant liability adjustment
  • Revenue was $0 vs $0.3M in Q1 2025 (no license revenue recognized)
  • Completed $37.2M private placement on April 1, 2026, with potential for additional $52.2M from warrant exercises
  • Cash, cash equivalents and investments of $72.4M at March 31, 2026, extending cash runway to mid-2029
  • GSK committed to Brexafemme relaunch with potential up to $146M in annual net sales milestones
  • Phase 2 proof-of-concept study for SCY-770 in ADPKD expected to begin Q4 2026 with early efficacy readout in H2 2027

Financial Impact

Net loss widened to $21.3M from $5.4M YoY; EPS miss of -$0.42 vs -$0.12 consensus; cash position $72.4M post-offering

epsnet incomerevenuecash

Risk Factors

  • No near-term revenue visibility; operating losses expected to continue
  • SCY-770 Phase 2 proof-of-concept study carries clinical and regulatory risk
  • Warrant liability fair value adjustment creates earnings volatility tied to stock price
  • Dilution risk from potential full exercise of $52.2M in warrants

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292371

Track record

14 reports on SCYX

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +12.34% at T+5 after the Mar 4, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
  2. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
  4. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
  5. Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
  6. Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
  7. Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
  8. Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
  9. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
  10. May 22, 202625w ago 8-K Neutral 4/10 Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026